Cargando…

Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management

BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) is an underrecognized syndrome characterized by chronic, progressive disease with a dismal prognosis. Frequent co-morbidities with a higher incidence than in idiopathic pulmonary fibrosis or emphysema alone are pulmonary hypertension (WHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Hage, René, Gautschi, Fiorenza, Steinack, Carolin, Schuurmans, Macé M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850450/
https://www.ncbi.nlm.nih.gov/pubmed/33536752
http://dx.doi.org/10.2147/COPD.S286360
_version_ 1783645446075318272
author Hage, René
Gautschi, Fiorenza
Steinack, Carolin
Schuurmans, Macé M
author_facet Hage, René
Gautschi, Fiorenza
Steinack, Carolin
Schuurmans, Macé M
author_sort Hage, René
collection PubMed
description BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) is an underrecognized syndrome characterized by chronic, progressive disease with a dismal prognosis. Frequent co-morbidities with a higher incidence than in idiopathic pulmonary fibrosis or emphysema alone are pulmonary hypertension (WHO group 3) in 47–90% of the patients and lung cancer in 46.8% of the patients. OBJECTIVE: Review current evidence and knowledge concerning diagnosis, risk factors, disease evolution and treatment options of CPFE. METHODS: We searched studies reporting CPFE in original papers, observational studies, case reports, and meta-analyses published between 1990 and August 2020, in the PubMed, Embase, Cochrane Library, Wiley Online Library databases and Google Scholar using the search terms [CPFE], [pulmonary fibrosis] OR [IPF] AND [emphysema]. Bibliographies of retrieved articles were searched as well. Further inclusion criteria were publications in English, French, German and Italian, with reference to humans. In vitro data and animal data were not considered unless they were mentioned in studies reporting predominantly human data. RESULTS: Between May 1, 1990, and September 1, 2020, we found 16 studies on CPFE from the online sources and bibliographies. A total of 890 patients are described in the literature. Although male/female ratio was not reported in all studies, the large majority of patients were male (at least 78%), most of them were current or former heavy smokers. CONCLUSION: CPFE is a syndrome presenting with dyspnea on exertion followed by disruptive cough and recurrent exacerbations. The disease may progress rapidly, be aggravated by pulmonary hypertension WHO group 3 and is associated with an increased risk of lung cancer. Smoking and male sex are important risk factors. There is a need for more research on CPFE especially relating to etiology, influence of genetics, treatment and prevention options. Antifibrotic therapy might be an interesting treatment option for these patients.
format Online
Article
Text
id pubmed-7850450
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78504502021-02-02 Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management Hage, René Gautschi, Fiorenza Steinack, Carolin Schuurmans, Macé M Int J Chron Obstruct Pulmon Dis Review BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) is an underrecognized syndrome characterized by chronic, progressive disease with a dismal prognosis. Frequent co-morbidities with a higher incidence than in idiopathic pulmonary fibrosis or emphysema alone are pulmonary hypertension (WHO group 3) in 47–90% of the patients and lung cancer in 46.8% of the patients. OBJECTIVE: Review current evidence and knowledge concerning diagnosis, risk factors, disease evolution and treatment options of CPFE. METHODS: We searched studies reporting CPFE in original papers, observational studies, case reports, and meta-analyses published between 1990 and August 2020, in the PubMed, Embase, Cochrane Library, Wiley Online Library databases and Google Scholar using the search terms [CPFE], [pulmonary fibrosis] OR [IPF] AND [emphysema]. Bibliographies of retrieved articles were searched as well. Further inclusion criteria were publications in English, French, German and Italian, with reference to humans. In vitro data and animal data were not considered unless they were mentioned in studies reporting predominantly human data. RESULTS: Between May 1, 1990, and September 1, 2020, we found 16 studies on CPFE from the online sources and bibliographies. A total of 890 patients are described in the literature. Although male/female ratio was not reported in all studies, the large majority of patients were male (at least 78%), most of them were current or former heavy smokers. CONCLUSION: CPFE is a syndrome presenting with dyspnea on exertion followed by disruptive cough and recurrent exacerbations. The disease may progress rapidly, be aggravated by pulmonary hypertension WHO group 3 and is associated with an increased risk of lung cancer. Smoking and male sex are important risk factors. There is a need for more research on CPFE especially relating to etiology, influence of genetics, treatment and prevention options. Antifibrotic therapy might be an interesting treatment option for these patients. Dove 2021-01-28 /pmc/articles/PMC7850450/ /pubmed/33536752 http://dx.doi.org/10.2147/COPD.S286360 Text en © 2021 Hage et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Hage, René
Gautschi, Fiorenza
Steinack, Carolin
Schuurmans, Macé M
Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
title Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
title_full Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
title_fullStr Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
title_full_unstemmed Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
title_short Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
title_sort combined pulmonary fibrosis and emphysema (cpfe) clinical features and management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850450/
https://www.ncbi.nlm.nih.gov/pubmed/33536752
http://dx.doi.org/10.2147/COPD.S286360
work_keys_str_mv AT hagerene combinedpulmonaryfibrosisandemphysemacpfeclinicalfeaturesandmanagement
AT gautschifiorenza combinedpulmonaryfibrosisandemphysemacpfeclinicalfeaturesandmanagement
AT steinackcarolin combinedpulmonaryfibrosisandemphysemacpfeclinicalfeaturesandmanagement
AT schuurmansmacem combinedpulmonaryfibrosisandemphysemacpfeclinicalfeaturesandmanagement